CD163 and scleroderma: Moreover, WKYMVm treatment did not reduce the numbers of CD68+CD163+ or CD68+Arginase-I+ M2 macrophages in scleroderma skin of Fpr2 KO mice, in contrast to the WKYMVm-induced decrease of M2 macrophage levels in that of wild type mice (Figure 7F).